Thinly traded AC Immune (ACIU +32.4%) is up a 16x surge in volume in apparent concert with Biogen’s (BIIB +17.9%) rally related to positive Phase 2 data on early Alzheimer’s candidate BAN2401, a humanized anti-amyloid beta protofil monoclonal antibody.
One of AC Immune’s Alzheimer’s candidates is crenezumab, in Phase 3 development by licensee Genentech, a humanized monoclonal antibody that binds to all forms of misfolded proteins, including Tau and beta amyloid.
Previously: Biogen +6% after Alzheimer’s drug succeeds in trial (July 5)
Previously: Biogen’s Alzheimer’s candidate BAN2401 flunks mid-stage study(Dec. 21, 2017)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.